Physician profile
Boniface Gitau
NPI 1023658663
$4,663.78
in general payments reported to CMS, 2019-2025
24 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,647 · 2022: $1,502 · 2023: $1,282 · 2024: $81.79 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $513.26 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $497.99 | 2021-2023 | Austedo |
| Vanda Pharmaceuticals INC. | $492.91 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $444.63 | 2021-2025 | |
| Lundbeck LLC | $410.55 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $372.74 | 2021-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $293.59 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $270.32 | 2021-2023 | Rexulti, Nuedexta |
| Bausch Health US, LLC | $209.66 | 2021-2023 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $191.05 | 2021-2023 | Belsomra |
| Eisai INC. | $163.47 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $160.48 | 2021-2022 | |
| Neos Therapeutics, LP | $110.13 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $105.16 | 2021-2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $77.89 | 2022-2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $74.98 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $71.36 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $63.09 | 2021-2022 | |
| Corium, LLC | $42.08 | 2023 | Azstarys |
| Almatica Pharma LLC | $35.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.15 | 2025 | Cobenfy |
| Biogen, INC. | $15.10 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.41 | 2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boniface Gitau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.